The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.
The management of invasive gram-positive infections, such as infective endocarditis (IE), requires an aggressive and prolonged treatment approach with specific antimicrobial treatment or a combination of effective antibiotics and infectious source control by surgery [1] . Dalbavancin, a novel lipoglycopeptide, was approved by the Food and Drug Administration and the European Medicines Agency for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) as a new therapeutic option for treatment of gram-positive bacterial infections [2] . Dalbavancin has in vitro activity against several gram-positive pathogens, including methicillin-resistant and vancomycin-intermediate susceptible strains of staphylococci and viridans group and β-hemolytic streptococci, Streptococcus pneumoniae, Enterococcus faecium, Enterococcus faecalis, and anerobic gram-positive cocci and bacilli [3] .
Resistance of dalbavancin to staphylococci is rare, being reported in <1% of isolates [3] . However, dalbavancin demonstrates poor activity against vancomycin-resistant Staphylococcus aureus and none against vancomycin-resistant enterococci expressing the VanA phenotype [3] . Dalbavancin has linear dose-related pharmacokinetics with an elimination half-life of approximately 346 hours, allowing a prolonged interval between 2 doses [4] . The approved dosage for dalbavancin in adults with ABSSSIs is a 2-dose regimen of 1000 mg on day 1 followed by 500 mg on day 8 [5] .
In our institution, General Hospital of Vienna, management of gram-positive infections and use of antibiotics, such as the glycopeptides vancomycin or teicoplanin and the lipoglycopeptide dalbavancin, is supervised by an infectious diseases specialist. In the last 3 years, dalbavancin was used in accordance with Austrian drug law to treat gram-positive infections, such as bacteremia with or without IE, osteomyelitis, spondylodiscitis, joint infections, and liver abscesses and as empirical therapy after hematopoietic stem cell transplantation. The objective of the current retrospective study was to evaluate the clinical outcomes and safety of dalbavancin in the treatment of IE caused by gram-positive bacteria.
MATERIAL AND METHODS
This retrospective cohort study was performed from January 2015 to December 2016 in the University Hospital of Vienna, Austria. After approval by the local ethics committee in 2017 (No. 1445/2017), we screened retrospectively for adult patients with gram-positive bacteremia with IE treated by ≥1 dose of dalbavancin. Demographic, clinicopathological, microbiological, and laboratory data were extracted retrospectively from the Vienna General Hospital Patient Information System. Patients were excluded if their medical records or microbiological culture results for gram-positive pathogens were not available. Demographic characteristics obtained from patients' medical records included sex, age, and source of infection. Gram-positive bacteremia was defined as ≥1 positive blood culture with S. aureus, Streptococcus spp., or Enterococcus spp. For coagulase-negative staphylococci or Aerococcus urinae, 2 positive blood cultures were required.
IE was defined according to the modified Duke criteria [1] . The primary end point was defined as clinical cure or failure. Clinical cure was defined as resolution of all clinical signs and symptoms of infection, no additional antibiotic therapy required for the indication initially treated with dalbavancin, absence of Gram-positive bacteraemia at the end of dalbavancin therapy and no microbiological relapse in follow-up 6 months after completion of treatment. Failure was defined as worsening of current infection or new or recurrent signs and symptoms of infection requiring either a change or addition of antibiotic therapy.
Secondary end points were defined as the number of patients treated primarily with dalbavancin (including the reason for this treatment), the reason for switching to dalbavancin in patients with other primary antimicrobial treatment, the number of patients using dalbavancin in outpatient settings (outpatient parenteral antimicrobial therapy [OPAT]), the duration of dalbavancin therapy, treatment regimen (once vs twice weekly), and adverse effects. Levels of creatinine (in milligrams per deciliter ) and liver enzymes (alanine aminotransferase and aspartate aminotransferase, in units per liter) were monitored at least at the beginning and the end of dalbavancin therapy (7-14 days after the last dose). All patients were followed up for 6 months after the last dose of dalbavancin.
The duration of therapy was calculated using the number of administered dalbavancin doses for the once-or twice-weekly regimen as follows: time (in weeks) for once-weekly regimen with 500 mg (loading dose, 1000 mg) = number of administered doses × 1; time (in weeks) for twice-weekly regimen with 1000 mg (loading dose, 1500 mg) = number of administered doses × 2.
RESULTS

Baseline Characteristics
A total of 31 patients with IE caused by gram-positive cocci who received at least a single dose of dalbavancin were screened. Four patients were excluded owing to missing clinical data. The final analysis included 27 patients (19 men and 8 women) with a median age of 60 years (range, 27-85 years), 16 with native valve IE, 6 with prosthetic valve IE, and 5 with cardiac devicerelated endocarditis (CDE). Surgical treatment of IE was performed in 11 of 16 patients (68.8%) with native valve IE (valve replacement), in 1 of 6 (16.7%) with prostethic valve IE, and in 4 of 5 (80%) with CDE (cardiac device replacement).
Microbiological and Clinical Outcomes
Microbiological and clinical successes were reached in 25 (92.6%) of the 27 patients who received dalbavancin as primary or sequential treatment for IE. In fact, 24 patients (88.9%) were previously treated with other antimicrobial agents ( Table 1) . In all those patients, negative blood cultures were obtained before the first dose of dalbavancin was administered. In 3 patients antimicrobial treatment was switched to dalbavancin in the hospital setting owing to poor venous access.
In 1 patient with E. faecalis prosthetic valve endocarditis, antimicrobial therapy was changed to dalbavancin after primary treatment with vancomycin. However, this patient died 1 week after the first dose of dalbavancin and 2 weeks after prosthetic valve replacement, owing to postoperative complications, and was therefore this classified as a clinical failure. In 23 patients, dalbavancin was switched to OPAT. However, in all cases ≥1 dose was given in the hospital setting, and dalbavancin was continued as OPAT. In 3 patients, dalbavancin was used as primary therapy for native valve IE (n = 1), prosthetic valve (n = 1), or CDE (n = 1) because it was the easiest therapy option for OPAT. In all 3 patients, no relapse was detected during 6 months of follow-up.
The median duration of dalbavancin therapy in the 27 patients with IE caused by gram-positive cocci was 6 weeks (range, 1-30 weeks). Nine patients (33.3%) were treated with once-weekly and 18 (66.6%) with twice-weekly regimens.
In 1 patient with a CDE due to a methicillin-susceptible S. aureus who received only incomplete surgical source control, dalbavancin therapy was discontinued owing to microbiological and clinical failure. This patient received dalbavancin in a once-weekly regimen for 30 weeks without any adverse effects. However, after initial clinical improvement and the presence of sterile blood cultures, the blood culture became positive again, with S. aureus on day 210. S. aureus showed small colony variants with increased minimal inhibitory concentration values of teicoplanin (16 mg/L) and vancomycin (2 mg/L).
Twenty-five patients had no documented adverse effects during long-term dalbavancin treatment. One patient experienced nausea and vomiting after the second dose of dalbavancin, but therapy was continued. In 1 patent who received a loading dose of 1500 mg for a twice-weekly regimen, a 2.5-fold increase in the serum creatinine level was seen after the first 2 weeks. In response, the following dose was reduced to 500 mg of dalbavancin every 2 weeks for the remaining treatment duration of 6 weeks, and creatinine values decreased again.
DISCUSSION
So far, dalbavancin has only been approved for the treatment of ABSSSIs. Further phase II studies for complicated bacteremia and IE are terminated, but data are not available yet (clinicaltrials.gov). In a rabbit model of experimental endocarditis due to S. aureus, dalbavancin given once daily for 4 days or as a single 40-mg/kg dose showed potency at least on par with vancomycin [6] . In a commentary on the 2015 European Society of Cardiology guidelines for infectious endocarditis, dalbavancin was discussed as a new option for outpatient treatment, but owing to a missing approval study it is an off-label therapy [7] .
Our clinical study evaluated the microbiological and clinical effectiveness and safety of prolonged dalbavancin treatment of gram-positive bacteremia with IE. The majority of our patients (92.6%) were infected by a β-lactam-sensitive gram-positive isolate. In Austria, the proportion of invasive S. aureus isolates resistant to methicillin is low at 5%-10%, compared with high resistance rates of 25%-50% in southern Europe or 43.2% in the United States [8, 9] . In the present study, dalbavancin was used in most cases only as sequential treatment when the bloodstream was already clearly by initial antimicrobial treatment. In a single case, resistance induction to glycopeptide antibiotics must be assumed. This patient with S. aureus CDE showed microbiological failure despite very long treatment duration of 30 weeks, most likely owing to insufficient source control. removal and appropriate antimicrobial treatment is required to enable clinical cure. In the literature, a relapse rate of 50% was reported for CDE when source control was not feasible [10] . In this special clinical case, the treating physicians chose dalbavancin monotherapy because recent data demonstrated biofilm activity of dalbavancin against methicillin-resistant staphylococci, at least in vitro [11] . Previously, Werth et al [12] reported a case of methicillin-resistant S. aureus central line-associated bloodstream infection in which dalbavancin and vancomycin nonsusceptibility emerged in a urine isolate collected after the patient was treated with vancomycin and dalbavancin sequentially. Steele et al [13] reported another case of clinical treatment failure of dalbavancin in a pregnant patient with methicillin-resistant S. aureus endocarditis, which occurred after 4 weeks of therapy with a once-weekly treatment regimen. Steele et al [13] reported induction of a vancomycin-intermediate S. aureus in this case and discussed this phenomenon due to exposure to subinhibitory concentrations of dalbavancin, which can result from altered pharmacokinetics in pregnancy.
In our study, the majority of patients (88.9%) were previously treated with another antimicrobial agent and dalbavancin was used as extended therapy. The main advantage of dalbavancin is its long half-life, and the reason for switching to dalbavancin was using it as OPAT in most cases. Although dalbavancin is an expensive drug, its use for OPAT treatment was reported to be highly cost-effective owing to earlier discharge and reduction in hospital day costs [14] .
In randomized phase 3 trials, dalbavancin was reported as a safe drug with significantly less adverse effects than vancomycin, particularly less kidney damage, in patients with ABSSSIs [15] . Our retrospective observational study confirmed that dalbavancin is also safe for prolonged treatment. The incidence of potential drug-induced nephrotoxicity was low at 3.7%. In 1 patient with nephrotoxicity, dose adjustment was necessary, but dalbavancin therapy was completed as initially recommended.
Furthermore, in the present study 2 different dalbavancin treatment regimens were used: 10 patients (37.0%) were treated with a once-weekly regimen, and 17 (63.0%) with a twiceweekly regimen. In the first year, most patients received the once-weekly, regimen and in the second year, most received the twice-weekly regimen. No differences in total duration of therapy and clinical response were seen. However, the patient with the temporary 2.5-fold creatinine increase received the higher loading dose of 1500 mg, owing to the twice-weekly regimen.
Our study has some limitations. First, it is only retrospective. Second, 24 of 27 patients had other initial antimicrobial therapies, which may have led to an overestimation of dalbavancin's clinical and microbiological success rates. In conclusion, we demonstrated that dalbavancin seems to be well tolerated in patients who received it as sequential or initial antimicrobial therapy for gram-positive infections with IE.
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